Physician profile
Gregory Niehauser
NPI 1518908250
$7,182.75
in general payments reported to CMS, 2019-2025
42 companies · $572 in 2025
The $572 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $1,063 · 2021: $1,234 · 2022: $1,275 · 2023: $1,401 · 2024: $564 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,537.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,535.44 | 2021-2025 | |
| Novo Nordisk INC | $897.01 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $495.70 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $480.93 | 2019-2023 | Xarelto |
| Abbott Laboratories | $412.01 | 2021-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $393.98 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $288.86 | 2019-2023 | Repatha |
| Allergan, INC. | $255.27 | 2019-2020 | |
| Glaxosmithkline, LLC. | $249.87 | 2019-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $247.11 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $241.05 | 2019-2022 | |
| Lilly USA, LLC | $193.67 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Channel Medsystems, INC. | $166.33 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.51 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $111.94 | 2021-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Niehauser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.